RGNXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

REGENXBIO Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$7.15+0.23 (+3.25%)

Close on Oct 19, 2026

Market cap: $379.06M
P/E (TTM): –
Dividend yield: –

Dividends

Regenxbio has not reported a dividend

No dividend per share appears in Regenxbio's annual filings since fiscal 2012.

Where these numbers come from

Parsed from the XBRL in Regenxbio's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is RGNX.

Revenue growth12.0% · median 158.9%

Operating margin-94.1% · median -214.2%

Net margin-112.6% · median -124.7%

Company	Revenue	Growth
MGTX	$397.50M	+948.3%
RGNX	$174.48M	+12.0%
BEAM	$156.04M	+158.9%
AGEN	$132.69M	+30.5%
FDMT	$92.01M	+278712.1%
SGMOQ	$34.56M	-45.8%

Company

Next earnings (est.): Nov 5, 2026, before open
Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 371
Held by institutions: 64.2%
Auditor: PricewaterhouseCoopers LLP
SEC CIK: 1590877

Advertisement
300 × 250